Suchergebnisse - "Fénix-Caballero, Silvia"

PubPharm (23)

1

Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system

enthalten in: The European journal of health economics : HEPAC : health economics in prevention and care | 2024

von Fenix-Caballero, S. | Sanchez-Vegas, A. | Alegre Del-Rey, E. | +3

2

Abemaciclib as adjuvant treatment for high-risk early breast cancer

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2024

von Ganfornina Andrades, A. | Fénix Caballero, S. | Salguero Olid, A. | +1

3

Abemaciclib as adjuvant treatment for high-risk early breast cancer

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2024

von Ganfornina Andrades, A. | Fénix Caballero, S. | Salguero Olid, A. | +1

4

Switching of anti-migraine antibodies : effectiveness or regression to the mean?

enthalten in: European journal of hospital pharmacy : science and practice | 2024

von Alegre-Del Rey, E. | Fénix-Caballero, S. | Domínguez-Santana, C.

5

Translated article] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2024

von Salmerón-Navas, F. | Barreiro-Fernández, E. | Fénix-Caballero, S.

6

Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2024

von Salmerón-Navas, F. | Barreiro-Fernández, E. | Fénix-Caballero, S.

7

Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2023

von Vila Pérez, A. | Alegre-Del Rey, E. | Fénix-Caballero, S. | +3

8

Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR

enthalten in: Supportive care in cancer | 2023

von Vila Pérez, A. | Alegre-del Rey, E. | Fénix-Caballero, S. | +3

9

Daratumumab-based therapies in transplant-ineligible patients with untreated multiple myeloma and hepatic dysfunction : A systematic review of subgroup analyses

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2023

von Gil-Sierra, M. | Briceño-Casado, M. | Fénix-Caballero, S. | +3

10

Systematic review and meta-analysis of interleulin-6 inhibitors in reducing mortality for hospitalized patients with COVID-19

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2022

von Alegre-Del-Rey, E. | Fénix-Caballero, S. | Salmerón-Navas, F. | +3